Immunome
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 55
- Market Cap
- $899M
- Website
- http://www.immunome.com
- Introduction
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Cardiac Liability Study of Varegacestat in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06855264
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Phase 1 Mass Balance Study of Varegacestat
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06845852
- Locations
- 🇺🇸
Frontage Laboratories, Inc., Secaucus, New Jersey, United States
A Varegacestat Hepatic Impairment Study
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT06841315
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Conditions
- Solid MalignanciesHematologic Malignancies
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT06823167
- Locations
- 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Sarah Cannon Research Institute - Oncology Partners, Nashville, Tennessee, United States
A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06677996
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
- Prev
- 1
- 2
- Next